MedTrace Logo

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

NCT07076030 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-01-28

No results posted yet for this study

Summary

This clinical research study is testing the study compound petrelintide that is being developed for the weight management in people with obesity or overweight with comorbidities or related diseases.

The aim of this clinical research study is to investigate whether the effects of petrelintide will be different in people with normal kidney function compared to people with impaired kidney function.

Conditions

  • Renal Impairment

Interventions

DRUG

Petrelintide

Solution administered with a syringe

Sponsors & Collaborators

Principal Investigators

  • Victoria Kegel-Hübner, Dr.med. · Charité Research Organisation GmbH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-15
Primary Completion
2025-11-25
Completion
2025-11-25
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07076030 on ClinicalTrials.gov